We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App


24 Feb 2024 - 28 Feb 2024
05 Mar 2024 - 07 Mar 2024

AI-Based Image Analysis Software Profiles Cancer Biomarkers in Real Time

By LabMedica International staff writers
Posted on 27 Mar 2023
Print article
Image: New research has opened a path for fast and accurate cancer diagnosis (Photo courtesy of Imagene)
Image: New research has opened a path for fast and accurate cancer diagnosis (Photo courtesy of Imagene)

Lung cancer is the most widespread type of cancer worldwide, resulting in approximately 1.76 million fatalities annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses and is typically identified at advanced stages. Due to the late detection of the disease, statistics show that 10-20% of NSCLC patients succumb within 1-3 months of diagnosis. Improving patient care and making targeted therapeutic decisions necessitates the identification of gene alterations. However, only 28% of cancer patients currently undergo a comprehensive analysis of all nine actionable cancer biomarkers, and up to 64% of lung cancer patients do not receive the best available treatment, primarily due to inadequate testing for biomarkers to determine the mutation's nature. Furthermore, in numerous instances, such as with NGS, sensitivity is significantly lower than expected, and interpretability is poor due to the requirement for highly trained specialists who understand what they are examining.

An innovative AI-based system from Imagene (Tel Aviv, Israel) can detect cancer biomarkers in real-time, potentially expediting the administration of treatment. Imagene's cutting-edge system utilizes a biopsy image, generating a biomarker report ready for diagnosis within minutes, precisely identifying the specific cancer mutation present in the biopsy. Currently, the time between biopsy and the initiation of treatment, during which cancer nature is evaluated, typically lasts for several weeks, frequently extending beyond a month. As this waiting period is too long for many patients, Imagene's technology has the potential to significantly reduce it, resulting in patients receiving diagnoses and treatment recommendations on the same day.

Detecting cancer mutations in patients and locations of diverse types is achievable with the aid of AI since cancer patterns tend to repeat themselves. Imagene combines self-supervised learning and other AI techniques, utilizing unlabeled data to enhance results, as well as proprietary processing of prepared data to analyze images. Imagene is presently collaborating with 28 diverse biomarkers across eight organs, demonstrating that their technology is standardized and yields accurate results, aiding in clinical decision-making. Currently, the technology is undergoing clinical research and will soon be commercialized while adhering to regulatory requirements. Ultimately, the technology is expected to be tissue-agnostic.

Related Links:

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
POCT Fluorescent Immunoassay Analyzer
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article


Clinical Chemistry

view channel
Image: Wireless Point-of-Care Testing for Hepatitis B Virus (Photo courtesy of Chulalongkorn University)

Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step

Hepatitis B, a significant global health concern, is responsible for chronic liver diseases like cirrhosis and liver cancer which is one of the most common cancers worldwide. The challenge with hepatitis... Read more

Molecular Diagnostics

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome

Antiphospholipid syndrome (APS) is an autoimmune disorder that typically presents as venous or arterial thrombosis and/or pregnancy loss. Diagnosing APS can be difficult as its symptoms often resemble... Read more


view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more


view channel
Image: The companies will develop genetic testing systems based on capillary electrophoresis sequencers (Photo courtesy of 123RF)

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.